NEW YORK, Oct. 16 – Atugen, a Berlin-based genomics company, said Tuesday it had signed a target validation deal with AstraZeneca.

Under the terms of the deal, Atugen will use its GeneBloc antisense technology to validate targets of interest to the British pharmaceutical company. The companies previously completed a target evaluation deal that dates back to 1999.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.